Sanford C. Bernstein
https://www.bernsteinresearch.comSanford C. Bernstein, a division of AllianceBernstein, is a research firm.
-
Novo Nordisk to halve US list price of Wegovy from 2027
-
What comes next for Eli Lilly (LLY) stock after $1T valuation?
-
Bernstein on IRA pricing: $245 really is the floor
-
Bernstein on Novo's Alzheimer's miss: 'Don't expect Lilly to stay quiet'
-
Analysis-Novo Nordisk CEO signals new appetite for risk in obesity deals
-
Novo Nordisk: Diabetes and obesity GLP-1 portfolio still attractive says Bernstein
-
Bernstein SocGen Group Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Outperform
-
Novo Nordisk earnings preview: Analysts cautious ahead of release
-
Bernstein Reiterates Market Perform on Novo Nordisk (NOVOB:DC) (NVO) Following NovoCare Pharmacy Launch
-
Bernstein Reiterates Market Perform Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
What's the current state of China's GLP-1 market?
-
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK620 at Bernstein SocGen Group
-
Bernstein explains why this Big Pharma stock should 'continue to work'
-
Bernstein explains why this big pharma stock continue to work
-
Bernstein SocGen Group Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Market Perform
-
Bernstein SocGen Group Reiterates Underperform Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Bernstein: 'GLP-1s vs. the Weight of the World'
-
Bernstein: 'Could the lion's share of China GLP-1 market go to domestic players?'
-
Will this be the next obesity stock to be acquired?
-
Bernstein Reiterates Outperform Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk targets bigger slice of diabetes market with new tablet
-
Bernstein Upgrades Novo Nordisk (NVO) to Outperform
-
Pre-Open Movers 06/08: (EDAP) (ZUMZ) (SFIX) Higher; (CXO) (MVIS) (LITE) Lower (more...)
-
NVO INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Novo Nordisk A/S
-
NVO INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Novo Nordisk A/S
-
Notable 52-Week Highs and Lows 9/9: (LXRX) (FNSR) (SWFT) High; (VMEM) (NCLH) (NVO) Low
-
Bernstein Downgrades Novo Nordisk (NVO) to Underperform
-
Sanford Bernstein Upgrades Novo Nordisk (NVO) to Outperform

